Indicator type;Size of the company;Total
Number of companies carrying out R&D in Biotechnology;Less than 250 employees;1,221
Number of companies carrying out R&D in Biotechnology;250 and more employees;156
Number of companies carrying out R&D in Biotechnology;Total;1,376
% Companies by type of biotechnology used: Genetic Code;Less than 250 employees;30.2
% Companies by type of biotechnology used: Genetic Code;250 and more employees;41.5
% Companies by type of biotechnology used: Genetic Code;Total;31.4
% Companies by type of biotechnology used: Functional Units;Less than 250 employees;42.4
% Companies by type of biotechnology used: Functional Units;250 and more employees;54.3
% Companies by type of biotechnology used: Functional Units;Total;43.7
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Less than 250 employees;21.2
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;250 and more employees;35.9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;22.8
% Companies by type of biotechnology used: Bioprocesses;Less than 250 employees;46.1
% Companies by type of biotechnology used: Bioprocesses;250 and more employees;65.3
% Companies by type of biotechnology used: Bioprocesses;Total;48.3
% Companies by type of biotechnology used: Subcellular Organisms;Less than 250 employees;7.0
% Companies by type of biotechnology used: Subcellular Organisms;250 and more employees;14.6
% Companies by type of biotechnology used: Subcellular Organisms;Total;7.9
% Companies by type of biotechnology used: Bioinformatics;Less than 250 employees;26.5
% Companies by type of biotechnology used: Bioinformatics;250 and more employees;32.5
% Companies by type of biotechnology used: Bioinformatics;Total;27.1
% Companies by type of biotechnology used: Nanobiotechnology;Less than 250 employees;11.0
% Companies by type of biotechnology used: Nanobiotechnology;250 and more employees;13.4
% Companies by type of biotechnology used: Nanobiotechnology;Total;11.2
% Companies by type of biotechnology used: Other;Less than 250 employees;18.1
% Companies by type of biotechnology used: Other;250 and more employees;14.0
% Companies by type of biotechnology used: Other;Total;17.6
Companies in which biotechnology activities are: Main and/or exclusive;Less than 250 employees;686
Companies in which biotechnology activities are: Main and/or exclusive;250 and more employees;25
Companies in which biotechnology activities are: Main and/or exclusive;Total;711
Companies in which biotechnology activities are: A secondary business line;Less than 250 employees;214
Companies in which biotechnology activities are: A secondary business line;250 and more employees;55
Companies in which biotechnology activities are: A secondary business line;Total;270
Companies in which biotechnology activities are: A necessary tool for production;Less than 250 employees;320
Companies in which biotechnology activities are: A necessary tool for production;250 and more employees;75
Companies in which biotechnology activities are: A necessary tool for production;Total;395
% Companies by final application areas of biotechnology use: Human Health;Less than 250 employees;48.7
% Companies by final application areas of biotechnology use: Human Health;250 and more employees;42.7
% Companies by final application areas of biotechnology use: Human Health;Total;48.0
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Less than 250 employees;16.7
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;250 and more employees;17.9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;16.9
% Companies by final application areas of biotechnology use: Food Products;Less than 250 employees;28.0
% Companies by final application areas of biotechnology use: Food Products;250 and more employees;40.1
% Companies by final application areas of biotechnology use: Food Products;Total;29.4
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Less than 250 employees;26.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry;250 and more employees;22.6
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;25.7
% Companies by final application areas of biotechnology use: Environment;Less than 250 employees;17.9
% Companies by final application areas of biotechnology use: Environment;250 and more employees;18.9
% Companies by final application areas of biotechnology use: Environment;Total;18.0
% Companies by final application areas of biotechnology use: Industry;Less than 250 employees;12.6
% Companies by final application areas of biotechnology use: Industry;250 and more employees;16.5
% Companies by final application areas of biotechnology use: Industry;Total;13.0
R&D personnel in Biotechnology (PP);Less than 250 employees;10,421
R&D personnel in Biotechnology (PP);250 and more employees;6,836
R&D personnel in Biotechnology (PP);Total;17,257
R&D personnel in Biotechnology (PP): Research personnel;Less than 250 employees;6,087
R&D personnel in Biotechnology (PP): Research personnel;250 and more employees;3,108
R&D personnel in Biotechnology (PP): Research personnel;Total;9,195
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Less than 250 employees;4,333
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;250 and more employees;3,728
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8,061
R&D personnel in Biotechnology (PP). Women;Less than 250 employees;5,700
R&D personnel in Biotechnology (PP). Women;250 and more employees;4,280
R&D personnel in Biotechnology (PP). Women;Total;9,980
R&D personnel in Biotechnology (PP). Women: Research personnel;Less than 250 employees;3,359
R&D personnel in Biotechnology (PP). Women: Research personnel;250 and more employees;1,863
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5,222
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Less than 250 employees;2,341
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;250 and more employees;2,417
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;4,758
R&D personnel in Biotechnology (FTE);Less than 250 employees;7,562.8
R&D personnel in Biotechnology (FTE);250 and more employees;5,320.6
R&D personnel in Biotechnology (FTE);Total;12,883.4
R&D personnel in Biotechnology (FTE): Research personnel;Less than 250 employees;4,665.3
R&D personnel in Biotechnology (FTE): Research personnel;250 and more employees;2,437.9
R&D personnel in Biotechnology (FTE): Research personnel;Total;7,103.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Less than 250 employees;2,897.4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;250 and more employees;2,882.8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;5,780.2
R&D personnel in Biotechnology (FTE). Women;Less than 250 employees;4,222.0
R&D personnel in Biotechnology (FTE). Women;250 and more employees;3,378.6
R&D personnel in Biotechnology (FTE). Women;Total;7,600.6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Less than 250 employees;2,605.7
R&D personnel in Biotechnology (FTE). Women: Research personnel;250 and more employees;1,451.3
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;4,057.0
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Less than 250 employees;1,616.3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;250 and more employees;1,927.3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3,543.7
Expenditure on internal R&D in Biotechnology (thousands of euros);Less than 250 employees;794,091
Expenditure on internal R&D in Biotechnology (thousands of euros);250 and more employees;489,255
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1,283,346
1) By type of expenditure: Current expenditure;Less than 250 employees;715,652
1) By type of expenditure: Current expenditure;250 and more employees;464,535
1) By type of expenditure: Current expenditure;Total;1,180,187
1.1) Labour expenditure of research personnel;Less than 250 employees;235,238
1.1) Labour expenditure of research personnel;250 and more employees;137,183
1.1) Labour expenditure of research personnel;Total;372,421
1.2) Labour expenditure of technical and auxiliary personnel;Less than 250 employees;113,075
1.2) Labour expenditure of technical and auxiliary personnel;250 and more employees;116,659
1.2) Labour expenditure of technical and auxiliary personnel;Total;229,734
1.3) Other current expenditure;Less than 250 employees;367,339
1.3) Other current expenditure;250 and more employees;210,693
1.3) Other current expenditure;Total;578,032
2) By type of expenditure: Capital expenditure;Less than 250 employees;78,439
2) By type of expenditure: Capital expenditure;250 and more employees;24,720
2) By type of expenditure: Capital expenditure;Total;103,159
2.1) Land and buildings;Less than 250 employees;8,547
2.1) Land and buildings;250 and more employees;2,342
2.1) Land and buildings;Total;10,889
2.2) Equipment and tools;Less than 250 employees;40,395
2.2) Equipment and tools;250 and more employees;18,809
2.2) Equipment and tools;Total;59,204
2.3) Acquisition of specific R&D software;Less than 250 employees;4,415
2.3) Acquisition of specific R&D software;250 and more employees;1,208
2.3) Acquisition of specific R&D software;Total;5,623
2.4) Other R&D-specific IP products;Less than 250 employees;25,082
2.4) Other R&D-specific IP products;250 and more employees;2,360
2.4) Other R&D-specific IP products;Total;27,442
1.1) By origin of funds: Own funds;Less than 250 employees;548,276
1.1) By origin of funds: Own funds;250 and more employees;339,251
1.1) By origin of funds: Own funds;Total;887,527
1.2) By origin of funds: Funds from the Business sector;Less than 250 employees;96,237
1.2) By origin of funds: Funds from the Business sector;250 and more employees;47,667
1.2) By origin of funds: Funds from the Business sector;Total;143,903
1.3) By origin of funds: Funds from the Public Administration sector;Less than 250 employees;98,923
1.3) By origin of funds: Funds from the Public Administration sector;250 and more employees;27,623
1.3) By origin of funds: Funds from the Public Administration sector;Total;126,546
1.4) By origin of funds: Funds from the Higher Education sector;Less than 250 employees;94
1.4) By origin of funds: Funds from the Higher Education sector;250 and more employees;0
1.4) By origin of funds: Funds from the Higher Education sector;Total;94
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Less than 250 employees;2,684
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;250 and more employees;9,939
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;12,623
1.6) By origin of funds: Funds from the rest of the world;Less than 250 employees;47,877
1.6) By origin of funds: Funds from the rest of the world;250 and more employees;64,776
1.6) By origin of funds: Funds from the rest of the world;Total;112,652
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Less than 250 employees;76,773
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);250 and more employees;60,659
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;137,432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Less than 250 employees;38,607
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;250 and more employees;49,521
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;88,127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Less than 250 employees;38,166
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;250 and more employees;11,139
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;49,305
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Less than 250 employees;46.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;250 and more employees;23.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;43.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Less than 250 employees;16.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;250 and more employees;15.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;16.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Less than 250 employees;24.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;250 and more employees;16.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;23.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Less than 250 employees;14.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;250 and more employees;14.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;14.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Less than 250 employees;19.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;250 and more employees;10.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;18.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Less than 250 employees;20.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;250 and more employees;12.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;19.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Less than 250 employees;18.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;250 and more employees;21.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;19.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Less than 250 employees;51.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;250 and more employees;40.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;49.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Less than 250 employees;61.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;250 and more employees;46.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;59.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Less than 250 employees;23.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;250 and more employees;11.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;22.3
% Companies with international revenues related to biotechnology activities;Less than 250 employees;23.6
% Companies with international revenues related to biotechnology activities;250 and more employees;22.7
% Companies with international revenues related to biotechnology activities;Total;23.6
% Companies representing international revenues related to biotechnology activities;Less than 250 employees;6.9
% Companies representing international revenues related to biotechnology activities;250 and more employees;1.0
% Companies representing international revenues related to biotechnology activities;Total;1.5
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Less than 250 employees;50.0
% International revenues related to biotechnology activities distributed in: Revenues from the EU;250 and more employees;62.8
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;57.6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Less than 250 employees;50.0
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;250 and more employees;37.2
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;42.4
% International revenues related to biotechnology activities by classification: International trade in goods and services;Less than 250 employees;91.4
% International revenues related to biotechnology activities by classification: International trade in goods and services;250 and more employees;76.2
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;82.3
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Less than 250 employees;4.5
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 and more employees;20.6
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;14.1
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Less than 250 employees;1.0
% International revenues related to biotechnology activities by classification: Subsidies from external sources;250 and more employees;1.8
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;1.5
% International revenues related to biotechnology activities by classification: Other;Less than 250 employees;3.1
% International revenues related to biotechnology activities by classification: Other;250 and more employees;1.4
% International revenues related to biotechnology activities by classification: Other;Total;2.1